Zabka Shares Drop 10% as Seven & i Abandons Investment Plans 
Zhongji Innolight Raises $6.8 Billion in Hong Kong IPO as AI Demand Fuels Growth 
Johnson & Johnson Proposes $5.5 Billion Talc Settlement to Resolve U.S. Ovarian Cancer Lawsuits 
Air Liquide Q2 Sales Growth Tops Forecast as Electronics Business Drives Strong Performance 
Serica Energy to Acquire Pharos Energy for £145.7M, Sending PHARP Shares Soaring 
Brown-Forman Rejects Sazerac’s $15 Billion Takeover Bid as Family Backs Independence 
BHP, Port Hedland Unions Fail to Reach Wage Deal as Negotiations Continue 
CATL Shares Jump as $5.6 Billion Buyback Signals Confidence in Long-Term Growth 
Galp Shares Fall After Q2 EBITDA Miss Despite Profit Beat and Higher Dividend 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
SK Hynix Q2 Profit Hits Record as AI Memory Chip Demand Fuels Growth 
Barclays Q2 Profit Beats Forecasts as Investment Banking Strength Offsets Higher Costs 
TSMC Gradually Restarts Japan Chip Plant After Kumamoto Earthquake 
Exosens H1 Profit Beats Forecasts as Defense Demand Drives Growth 
Stellantis Sells Free2move Car-Sharing Business to Mutares to Strengthen Core Auto Strategy 
CXMT IPO Debut in Shanghai Puts $85.5 Billion Chipmaker in Spotlight 
Pfizer Inc. revealed that it received informal requests relating to its operations in China from the US Department of Justice and the US Securities and Exchange Commission (SEC) in June and August.
According to Pfizer, it is producing records to satisfy requests for documents from the Foreign Corrupt Practices Act units of the Justice Department and the SEC.
The 1977 Foreign Corrupt Practices Act makes it illegal for US firms and those whose stock is traded in the US to bribe foreign government officials.
In 2012, the drugmaker had to shell out $26.3 million as a settlement for illegal payments in winning overseas deals, including those in Russia, Bulgaria, China, the Middle East, and Italy.
China is a big growth market for global pharmaceutical companies. But they have to face tightened regulations, heightened tensions between China and the US, and China’s efforts to promote local generic drugmakers.
